GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Other Net Income (Loss)

Nanopharmaceutics (Nanopharmaceutics) Other Net Income (Loss) : $0.00 Mil (TTM As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics Other Net Income (Loss)?

Nanopharmaceutics's Other Net Income (Loss) for the three months ended in Sep. 2018 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2018 was $0.00 Mil.

Nanopharmaceutics's quarterly Other Net Income (Loss) declined from Mar. 2018 ($0.00 Mil) to Jun. 2018 ($0.00 Mil) but then stayed the same from Jun. 2018 ($0.00 Mil) to Sep. 2018 ($0.00 Mil).

Nanopharmaceutics's annual Other Net Income (Loss) stayed the same from Dec. 2015 ($0.00 Mil) to Dec. 2016 ($0.00 Mil) but then declined from Dec. 2016 ($0.00 Mil) to Dec. 2017 ($-0.00 Mil).

Nanopharmaceutics Other Net Income (Loss) Historical Data

The historical data trend for Nanopharmaceutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics Other Net Income (Loss) Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
Other Net Income (Loss)
- - -

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Nanopharmaceutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanopharmaceutics (Nanopharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Other Net Income (Loss)
Comparable Companies
MIII TSE:5363 TSE:7721 TSE:5821 TSX:AEF SDOIA DFM:GGICO SAU:2120 ABWN COL:RICH.N0000 CNAC MIL:SPRT XSGO:QUEMCHI TSE:3353 COL:VONE.N0000 XPAE:APIC MIL:CRS ELEC ATH:MIG XCNQ:MARI
Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Website
https://www.nanopharmaceutics.com
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.